Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5119]
News [14834]
Articles [105]
Editorials [3]
Conferences [245]
elearning [21]
Radiogenomic evaluation of tumour response to targeted agents
Dr Ronald Korn - CMO and founder of Imaging Endpoints, Scottsdale, USA
Radiogenomic evaluation of tumour response to targeted agents ( Dr Ronald Korn - CMO and founder of Imaging Endpoints, Scottsdale, USA )
10 Mar 2015
New drugs and targets in haematological malignancies
Dr Renier Brentjens - Memorial Sloan Kettering Cancer Center, New York, USA
New drugs and targets in haematological malignancies ( Dr Renier Brentjens - Memorial Sloan Kettering Cancer Center, New York, USA )
10 Mar 2015
Mutant-specific kinase inhibitors and TAT highlights
Prof Jean-Charles Soria - Institut Gustave Roussy, Paris, France
Mutant-specific kinase inhibitors and TAT highlights ( Prof Jean-Charles Soria - Institut Gustave Roussy, Paris, France )
10 Mar 2015
Drugging the cancer genome to overcome drug resistance
Prof Paul Workman - Institute of Cancer Research, UK
Drugging the cancer genome to overcome drug resistance ( Prof Paul Workman - Institute of Cancer Research, UK )
10 Mar 2015
ecancermedicalscience editor's choice for February 2015
Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy
ecancermedicalscience editor's choice for February 2015 ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )
3 Mar 2015
Adjuvant treatment with sorafenib or sunitinib does not improve outcomes in...
Dr Mark Beresford - Royal United Hospitals Bath, Bath, UK
Adjuvant treatment with sorafenib or sunitinib does not improve outcomes in localised renal carcinoma ( Dr Mark Beresford - Royal United Hospitals Bath, Bath, UK )
28 Feb 2015
Expert commentary on emerging research in genitourinary cancer
Dr Chris Parker - The Royal Marsden Hospital, London, UK
Expert commentary on emerging research in genitourinary cancer ( Dr Chris Parker - The Royal Marsden Hospital, London, UK )
28 Feb 2015
Combination of dalantercept plus axitinib versus placebo plus axitinib in...
Dr Martin Voss - Memorial Sloan Kettering Cancer Centre, New York City, USA
Combination of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma ( Dr Martin Voss - Memorial Sloan Kettering Cancer Centre, New York City, USA )
28 Feb 2015
VEGF targeted therapy and chemo an active combination in rapidly progressive...
Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA
VEGF targeted therapy and chemo an active combination in rapidly progressive renal cell carcinoma ( Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA )
27 Feb 2015
Impact of statins on survival outcomes in metastatic renal cell carcinoma
Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA
Impact of statins on survival outcomes in metastatic renal cell carcinoma ( Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA )
27 Feb 2015
Genomic profiling may reveal new drug targets in urothelial carcinoma
Dr Jeffrey Ross - Albany Medical College, Albany, USA
Genomic profiling may reveal new drug targets in urothelial carcinoma ( Dr Jeffrey Ross - Albany Medical College, Albany, USA )
27 Feb 2015
Combination of abiraterone and cabazitaxel in metastatic castration-resistant...
Dr Joaquin Mateo - Institute of Cancer Research, London, UK
Combination of abiraterone and cabazitaxel in metastatic castration-resistant prostate cancer ( Dr Joaquin Mateo - Institute of Cancer Research, London, UK )
27 Feb 2015

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation